Drug · FAERS side-effect profile with label screen

Nivolumab and Relatlimab-Rmbw side effects: what 472 FDA adverse event reports show

Nivolumab And Relatlimab-Rmbw · 4 reaction terms · 76 drug–reaction co-reports · data 2026-09-14

Drug class

Programmed Death Receptor-1 Blocking Antibody

FDA label (Established Pharmacologic Class) of the closest related product

Label matched

Nivolumab (Opdivo)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

472 reports · 67% serious · 95 with death outcome · 41% female

openFDA FAERS counts, all years, deduplication not applied

Used for

OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

FDA label, Indications and Usage

What it is

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 3 strongest signals

Labeled adverse reaction 1Reporting / coding artifact 2

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Myocarditis	19	74.7 48.0–116.0ROR 77.7 · χ² 1,307 / p 2e-286	69.5 EB05 47.1 · IC025 +3.9 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 64.6	no trial data cached
Malignant neoplasm progression	34	14.8 10.7–20.5ROR 15.9 · χ² 427 / p 4e-95	14.6 EB05 10.7 · IC025 +3.1 3/3 methods agree	Reporting / coding artifact	serious PRR 13.1	no trial data cached
Product storage error	19	9.8 6.3–15.2ROR 10.1 · χ² 141 / p 7e-33	8.7 EB05 5.6 · IC025 +2.2 3/3 methods agree	Reporting / coding artifact	–	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Malignant neoplasm progression	34	14.8 10.7–20.5ROR 15.9 · χ² 427 / p 4e-95	14.6 EB05 10.7 · IC025 +3.1 3/3 methods agree	Reporting / coding artifact	serious PRR 13.1	no trial data cached
Product storage error	19	9.8 6.3–15.2ROR 10.1 · χ² 141 / p 7e-33	8.7 EB05 5.6 · IC025 +2.2 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Myocarditis	19	74.7 48.0–116.0ROR 77.7 · χ² 1,307 / p 2e-286	69.5 EB05 47.1 · IC025 +3.9 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 64.6	no trial data cached
Malignant melanoma	4	13.2 5.0–35.2ROR 13.4 · χ² 34 / p 3e-9	7.9 EB05 2.7 · IC025 +0.7 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious PRR 11.6	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Nivolumab (checkpoint inhibitors) ↔ Immune-mediated colitis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Nivolumab and Relatlimab-Rmbw?

In FDA FAERS, the most frequently co-reported reaction terms for Nivolumab and Relatlimab-Rmbw are myocarditis, malignant melanoma. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Nivolumab and Relatlimab-Rmbw have an FDA boxed warning?

No. The FDA label retrieved for Nivolumab and Relatlimab-Rmbw has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Nivolumab and Relatlimab-Rmbw causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID f570b9c4-6846-4de2-abfa-4d0a4ae4e394, effective 20260812; matched on openfda.generic_name.exact:"NIVOLUMAB")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 4 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.